Lolis E - Search Results

1

MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model.

Tilstam PV, Schulte W, Holowka T, Kim BS, Nouws J, Sauler M, Piecychna M, Pantouris G, Lolis E, Leng L, Bernhagen J, Fingerle-Rowson G, Bucala R. Tilstam PV, et al. Among authors: lolis e. J Clin Invest. 2021 Dec 1;131(23):e127171. doi: 10.1172/JCI127171. J Clin Invest. 2021. PMID: 34850744 Free PMC article.

2

Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor.

Sun HW, Bernhagen J, Bucala R, Lolis E. Sun HW, et al. Among authors: lolis e. Proc Natl Acad Sci U S A. 1996 May 28;93(11):5191-6. doi: 10.1073/pnas.93.11.5191. Proc Natl Acad Sci U S A. 1996. PMID: 8643551 Free PMC article.

3

The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer.

Sun HW, Swope M, Cinquina C, Bedarkar S, Bernhagen J, Bucala R, Lolis E. Sun HW, et al. Among authors: lolis e. Protein Eng. 1996 Aug;9(8):631-5. doi: 10.1093/protein/9.8.631. Protein Eng. 1996. PMID: 8875640

4

Crystal structure of macrophage migration inhibitory factor (MIF), a glucocorticoid-induced regulator of cytokine production, reveals a unique architecture.

Lolis E, Bucala R. Lolis E, et al. Proc Assoc Am Physicians. 1996 Nov;108(6):415-9. Proc Assoc Am Physicians. 1996. PMID: 8956364 Review.

5

Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity.

Dios A, Mitchell RA, Aljabari B, Lubetsky J, O'Connor K, Liao H, Senter PD, Manogue KR, Lolis E, Metz C, Bucala R, Callaway DJ, Al-Abed Y. Dios A, et al. Among authors: lolis e. J Med Chem. 2002 Jun 6;45(12):2410-6. doi: 10.1021/jm010534q. J Med Chem. 2002. PMID: 12036350

6

Macrophage migration inhibitory factor.

Lolis E, Bucala R. Lolis E, et al. Expert Opin Ther Targets. 2003 Apr;7(2):153-64. doi: 10.1517/14728222.7.2.153. Expert Opin Ther Targets. 2003. PMID: 12667094 Review.

7

Therapeutic approaches to innate immunity: severe sepsis and septic shock.

Lolis E, Bucala R. Lolis E, et al. Nat Rev Drug Discov. 2003 Aug;2(8):635-45. doi: 10.1038/nrd1153. Nat Rev Drug Discov. 2003. PMID: 12904813 Review. No abstract available.

8

Macrophage migration inhibitory factor promotes intestinal tumorigenesis.

Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, Leng L, Lubetsky JB, Jin KK, Lolis E, Medina F, Brieva JA, Poulsom R, Markham AF, Bucala R, Hull MA. Wilson JM, et al. Among authors: lolis e. Gastroenterology. 2005 Nov;129(5):1485-503. doi: 10.1053/j.gastro.2005.07.061. Gastroenterology. 2005. PMID: 16285950

9

Macrophage migration inhibitory factor: a critical component of autoimmune inflammatory diseases.

Bucala R, Lolis E. Bucala R, et al. Among authors: lolis e. Drug News Perspect. 2005 Sep;18(7):417-26. doi: 10.1358/dnp.2005.18.7.939345. Drug News Perspect. 2005. PMID: 16362080 Free article. Review.

10

CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex.

Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, Bucala R. Shi X, et al. Among authors: lolis e. Immunity. 2006 Oct;25(4):595-606. doi: 10.1016/j.immuni.2006.08.020. Immunity. 2006. PMID: 17045821 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

148 results

Search Page